ARROW is an ongoing multicenter phase I/II trial which aims to assess both the safety and efficacy of pralsetinib, a potent and oral selective RET inhibitor, in patients with RET fusion-positive solid tumors, including NSCLC [131]. Here, RET is linked to non-small cell lung carcinoma.